文献速递心血管胸部CT

非胰岛素降糖药对糖尿病患者冠脉斑块进展影响的CCTA比较

Comparison of non-insulin glucose-lowering therapies on coronary atherosclerotic plaque progression in diabetes.
PubMed 文献 · Radiol Med · 2026-07-24

本研究基于TOCCATA注册研究,回顾性分析880次系列冠脉CTA扫描,比较五类非胰岛素降糖药对2型糖尿病患者冠脉粥样硬化进展的影响。结果显示GLP-1受体激动剂与血管水平狭窄进展显著减缓相关,而SGLT2i、二甲双胍及TZD未显示类似保护作用。

要点

  • GLP-1受体激动剂显著延缓冠脉狭窄进展,HR 0.68(95%CI 0.49-0.95)
  • SGLT2i未显示减缓斑块进展的保护作用,SSS进展HR 1.23(95%CI 1.00-1.52)
  • CCTA可作为评估降糖药心血管获益的影像学工具

核心结论

  • GLP-1受体激动剂与其他降糖药相比显著减缓冠脉斑块进展,或对晚期动脉粥样硬化患者有额外获益
  • SGLT2i未显示类似的斑块保护效应,提示CCTA可用于指导2型糖尿病个体化治疗决策

研究设计与样本

  • 回顾性、基于注册研究的队列研究,纳入TOCCATA注册研究中2型糖尿病患者的880次系列冠脉CTA扫描
  • 依据处方分层:二甲双胍357例、DPP-4抑制剂97例、GLP-1受体激动剂88例、SGLT2i 258例、TZD 80例
  • 主要终点为血管水平狭窄进展和患者水平斑块评分变化,包括MAXS、SIS、SSS
  • 采用多变量Cox回归模型校正相关协变量进行分析

关键影像表现/征象

  • GLP-1受体激动剂与血管水平狭窄进展的显著减少相关,校正HR 0.68(95%CI 0.49-0.95,p=0.024)
  • GLP-1受体激动剂在所有患者水平斑块评分上均一致抑制进展:MAXS HR 0.34(p=0.002)
  • GLP-1受体激动剂对SIS的HR为0.34(p<0.001),对SSS的HR为0.41(p<0.001)
  • SGLT2i对狭窄进展无显著影响,HR 0.99(95%CI 0.82-1.19,p=0.90)
  • DPP-4抑制剂显示狭窄进展增加趋势,HR 1.31(95%CI 1.01-1.69,p=0.039)

诊断标准与关键数值

  • 血管水平狭窄进展:GLP-1受体激动剂校正HR 0.68(95%CI 0.49-0.95,p=0.024)
  • 患者水平斑块评分:GLP-1受体激动剂MAXS HR 0.34(p=0.002),SIS HR 0.34(p<0.001),SSS HR 0.41(p<0.001)
  • SGLT2i狭窄进展HR 0.99(95%CI 0.82-1.19,p=0.90),SSS进展HR 1.23(95%CI 1.00-1.52,p=0.055)
  • DPP-4抑制剂狭窄进展HR 1.31(95%CI 1.01-1.69,p=0.039)

临床应用与阅片要点

  • 对接受GLP-1受体激动剂治疗的糖尿病患者,系列CCTA随访可预期观察到斑块进展减缓
  • 对SGLT2i治疗患者不应预期冠脉斑块体积或狭窄程度的影像学改善
  • DPP-4抑制剂治疗患者行CCTA随访时应关注狭窄进展的可能性
  • CCTA斑块评分可用于监测降糖治疗的心血管影像学疗效

局限性

  • 回顾性研究设计
  • 基于注册研究的观察性分析,治疗分配非随机化

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: The comparative effects of non-insulin glucose-lowering therapies on coronary plaque progression in type 2 diabetes (T2DM) remain unclear. This study aimed to evaluate the impact of five major classes of non-insulin therapies on the progression of coronary atherosclerosis using serial coronary computed tomography angiography (CCTA).

MATERIAL AND METHODS: This was a retrospective, registry-based cohort study analyzing 880 serial CCTA scans from patients with T2DM enrolled in the TOCCATA (Tomography of Coronary Artery Plaque and Treatment) registry. Patients were stratified based on their prescribed therapy: metformin (n = 357), dipeptidyl peptidase-4 (DPP-4) inhibitors (n = 97), glucagon-like peptide-1 receptor agonists (GLP-1 RAs, n = 88), sodium-glucose cotransporter-2 inhibitors (SGLT2i, n = 258), and thiazolidinediones (TZDs, n = 80). The primary endpoints were vessel-level stenosis progression and changes in patient-level plaque scores, including the Maximum coronary stenosis score (MAXS), segment involvement score (SIS), and segment stenosis score (SSS). Multivariable Cox regression models, adjusted for relevant covariates, were used for the analysis.

RESULTS: GLP-1 RAs were associated with the most significant reduction in vessel-level stenosis progression (adjusted Hazard Ratio [HR] 0.68, 95% Confidence Interval [CI]: 0.49-0.95, p = 0.024). This therapy class also consistently inhibited patient-level plaque progression across all scores (MAXS: HR 0.34, p = 0.002; SIS: HR 0.34, p < 0.001; SSS: HR 0.41, p < 0.001).In contrast, SGLT2i showed no significant effect on stenosis progression (HR 0.99, 95% CI: 0.82-1.19, p = 0.90) or SSS progression (HR 1.23, 95% CI: 1.00-1.52, p = 0.055). DPP-4 inhibitors showed a trend toward increased stenosis progression (HR 1.31, 95% CI: 1.01-1.69, p = 0.039). Metformin and TZDs had neutral effects on plaque progression.

CONCLUSION: In this real-world cohort of patients with type 2 diabetes, GLP-1 receptor agonists were associated with significantly slower coronary plaque progression compared to other glucose-lowering therapies. Other therapies, including SGLT2i, demonstrated no similar protective effects. These findings suggest that GLP-1 receptor agonists may offer particular benefits for patients with advanced atherosclerosis and underscore the potential value of CCTA in informing personalized therapeutic decisions in type 2 diabetes management.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Liu, Zhang, Chen, et al. Comparison of non-insulin glucose-lowering therapies on coronary atherosclerotic plaque progression in diabetes. Radiol Med. 2026. PMID: 42496918. doi:10.1007/s11547-026-02237-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。